Facebook Twitter Newsletter Linkedin RSS

Portail de la presse
INA_CATEGORYNET_728x90 Inpharmatica Announces PharmaCarta(TM) Partnership with Pfizer

Inpharmatica Announces PharmaCarta(TM) Partnership with Pfizer

Press and analyst contact
Andrew Lloyd & Associates
Andrew Lloyd / Guillaume Zeller
Tel: +33  1 56 54 07 00
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser. / Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

Inpharmatica Ltd        John Lisle, Chief Executive Officer
 Tel: +44 (0)20 7074 4600
Dr Vimal Mehta, Sr. VP Business Development        Tel: +1 203 453 6525

Inpharmatica Announces PharmaCarta(TM) Partnership with Pfizer

London, UK, 25th January 2005 - Inpharmatica Ltd, the drug discovery company, today announced a series of agreements with Pfizer. This provides Pfizer with access to four core components of Inpharmatica's PharmaCarta(TM) gene to candidate technology platform. These components are provided to Pfizer in addition to their Biopendium(TM) subscription, which now moves into its sixth year. The financial terms of the agreement are not disclosed.

Inpharmatica will use its proprietary technology for target druggability assessment; Pfizer will gain access to StARLITeTM, a database containing 20 years of curated medicinal chemistry information on compound structure and bioactivity linked to targets; to DrugStore(TM), a curated database of all known drugs, linked with their targets; and to AdmensaTM, Inpharmatica's proprietary technology for assessing the ADME (absorption, distribution, metabolism, and excretion) characteristics of therapeutic compounds and compound libraries.

PharmaCarta(TM) is Inpharmatica's gene to candidate platform, which bridges the gap between biology and chemistry. PharmaCarta facilitates target selection through druggability assessment linked to electronic identification of potential compounds biased for good drug-like characteristics.

Commenting on the announcement, John Lisle, Chief Executive Officer of Inpharmatica, said:
"This is a very exciting partnership for Inpharmatica. Pfizer has been a long-standing customer of Inpharmatica by subscribing to BiopendiumTM, and we are very pleased that this relationship has now grown to encompass additional components of Inpharmatica's PharmaCarta platform. In particular we are delighted to be adding value to Pfizer's already world-class expertise in assessing target druggability through their use of our technology. We look forward to this new partnership with Pfizer.

Notes to Editors:
Inpharmatica: http://www.inpharmatica.com
Founded in 1998, Inpharmatica Ltd is a drug discovery company using predictive technologies to improve speed and productivity. Focusing on highly druggable targets, its unique proprietary platform, PharmaCarta(TM), is an integrated suite of informatics-based technologies fully capable of rapid gene to candidate operations. Inpharmatica's lead discovery programme is focused on generating pre-clinical candidates against 16 novel nuclear receptors - proteins widely considered to be both druggable and of high therapeutic interest. Other significant portfolio targets include novel secreted proteins/antibodies, ion channels, P450 enzymes, metalloproteinases and progestin receptors.
The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some 50 million pounds (USD92m) from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, P&G, Daiichi, Riken, Taisho, Chugai, UCB Pharma, Ionix, CellZome and MDL.
--
Stéphanie CHANE CHICK TE

ANDREW LLOYD & ASSOCIATES
http://www.ala.com

55 rue Boissonade
75014 PARIS
FRANCE

Tel  : +33-1 56 54 07 00
Fax : +33-1 56 54 07 01

Brighton Business Centre
95 Ditchling Road
Brighton BN 1 4ST
ENGLAND

Tel:  +44-1273 675100
Fax: +44-1273 675400

email : Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

INTERNATIONAL TECHNOLOGY MARKETS            STRATEGY & COMMUNICATIONS